ZA200403396B - High level constitutive production of anthrax protective antigen. - Google Patents

High level constitutive production of anthrax protective antigen. Download PDF

Info

Publication number: ZA200403396B
Authority: ZA; South Africa
Prior art keywords: cells; protective antigen; recombinant; coli; culture
Prior art date: 2001-11-05

Application number

ZA200403396A

Other languages

English (en)

Inventor

Bhatnagar Rakesh

Syed Mohsin Waheed

Vibha Chauhan

Original Assignee

Bhatnagar Rakesh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-05

Filing date

2004-05-05

Publication date

2005-08-05

2004-05-05 Application filed by Bhatnagar Rakesh filed Critical Bhatnagar Rakesh

2005-08-05 Publication of ZA200403396B publication Critical patent/ZA200403396B/en

Links

101710194807 Protective antigen Proteins 0.000 title claims abstract description 63
241000193738 Bacillus anthracis Species 0.000 title claims abstract description 28
238000004519 manufacturing process Methods 0.000 title claims abstract description 13
238000000034 method Methods 0.000 claims abstract description 35
241000588724 Escherichia coli Species 0.000 claims abstract description 27
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 26
230000008569 process Effects 0.000 claims abstract description 16
239000004202 carbamide Substances 0.000 claims abstract description 14
230000014509 gene expression Effects 0.000 claims abstract description 14
238000000855 fermentation Methods 0.000 claims abstract description 11
230000004151 fermentation Effects 0.000 claims abstract description 11
238000005119 centrifugation Methods 0.000 claims abstract description 10
239000006228 supernatant Substances 0.000 claims abstract description 8
238000003306 harvesting Methods 0.000 claims abstract description 7
239000013613 expression plasmid Substances 0.000 claims abstract description 6
230000001131 transforming effect Effects 0.000 claims abstract description 4
238000001262 western blot Methods 0.000 claims abstract description 4
230000009089 cytolysis Effects 0.000 claims abstract description 3
238000012360 testing method Methods 0.000 claims abstract description 3
238000003936 denaturing gel electrophoresis Methods 0.000 claims abstract 2
210000004027 cell Anatomy 0.000 claims description 77
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 48
239000002609 medium Substances 0.000 claims description 18
239000013612 plasmid Substances 0.000 claims description 13
239000013589 supplement Substances 0.000 claims description 11
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
239000008103 glucose Substances 0.000 claims description 10
229940065181 bacillus anthracis Drugs 0.000 claims description 9
239000001963 growth medium Substances 0.000 claims description 8
235000015097 nutrients Nutrition 0.000 claims description 8
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
150000001720 carbohydrates Chemical class 0.000 claims description 7
230000003287 optical effect Effects 0.000 claims description 7
210000003000 inclusion body Anatomy 0.000 claims description 6
150000007524 organic acids Chemical class 0.000 claims description 6
229920005862 polyol Polymers 0.000 claims description 6
150000003077 polyols Chemical class 0.000 claims description 6
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 5
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
239000008101 lactose Substances 0.000 claims description 5
239000001630 malic acid Substances 0.000 claims description 5
235000011090 malic acid Nutrition 0.000 claims description 5
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
229930091371 Fructose Natural products 0.000 claims description 4
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
239000005715 Fructose Substances 0.000 claims description 4
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
229930182830 galactose Natural products 0.000 claims description 4
238000012807 shake-flask culturing Methods 0.000 claims description 4
239000013598 vector Substances 0.000 claims description 4
241000894006 Bacteria Species 0.000 claims description 3
239000006227 byproduct Substances 0.000 claims description 3
238000004587 chromatography analysis Methods 0.000 claims description 2
102000037865 fusion proteins Human genes 0.000 claims description 2
108020001507 fusion proteins Proteins 0.000 claims description 2
150000004676 glycans Chemical class 0.000 claims description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
239000012535 impurity Substances 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
230000003381 solubilizing effect Effects 0.000 claims description 2
238000003756 stirring Methods 0.000 claims description 2
101150105115 PA gene Proteins 0.000 abstract description 3
241000620209 Escherichia coli DH5[alpha] Species 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 description 25
102000004169 proteins and genes Human genes 0.000 description 24
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 18
229910052799 carbon Inorganic materials 0.000 description 18
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 11
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 11
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
239000001301 oxygen Substances 0.000 description 11
229910052760 oxygen Inorganic materials 0.000 description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 10
239000000758 substrate Substances 0.000 description 10
238000000746 purification Methods 0.000 description 8
230000015572 biosynthetic process Effects 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
230000012010 growth Effects 0.000 description 6
239000000047 product Substances 0.000 description 6
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 6
238000002360 preparation method Methods 0.000 description 5
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 4
230000004044 response Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
230000014616 translation Effects 0.000 description 4
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
238000009825 accumulation Methods 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000008859 change Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000006919 modified lb Substances 0.000 description 3
239000008188 pellet Substances 0.000 description 3
229910000160 potassium phosphate Inorganic materials 0.000 description 3
235000011009 potassium phosphates Nutrition 0.000 description 3
230000009467 reduction Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
238000013518 transcription Methods 0.000 description 3
230000035897 transcription Effects 0.000 description 3
229960005486 vaccine Drugs 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
244000063299 Bacillus subtilis Species 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
102100024423 Carbonic anhydrase 9 Human genes 0.000 description 2
101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
229960000723 ampicillin Drugs 0.000 description 2
229960002235 anthrax antigen Drugs 0.000 description 2
239000002518 antifoaming agent Substances 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
230000010261 cell growth Effects 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
238000002784 cytotoxicity assay Methods 0.000 description 2
231100000263 cytotoxicity test Toxicity 0.000 description 2
239000013578 denaturing buffer Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000004907 flux Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000011573 trace mineral Substances 0.000 description 2
235000013619 trace mineral Nutrition 0.000 description 2
238000013519 translation Methods 0.000 description 2
241000701447 unidentified baculovirus Species 0.000 description 2
230000035899 viability Effects 0.000 description 2
JDIIGWSSTNUWGK-UHFFFAOYSA-N 1h-imidazol-3-ium;chloride Chemical compound [Cl-].[NH2+]1C=CN=C1 JDIIGWSSTNUWGK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
241000304886 Bacilli Species 0.000 description 1
239000002028 Biomass Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
239000006137 Luria-Bertani broth Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
208000035472 Zoonoses Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229940037003 alum Drugs 0.000 description 1
-1 ammonium ions Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003254 anti-foaming effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
230000006860 carbon metabolism Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000013522 chelant Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000012364 cultivation method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
238000000326 densiometry Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
230000034659 glycolysis Effects 0.000 description 1
230000017525 heat dissipation Effects 0.000 description 1
108091008147 housekeeping proteins Proteins 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000006166 lysate Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000013028 medium composition Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
230000037353 metabolic pathway Effects 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000002018 overexpression Effects 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
239000008057 potassium phosphate buffer Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000011027 product recovery Methods 0.000 description 1
230000000601 reactogenic effect Effects 0.000 description 1
238000004153 renaturation Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
238000012546 transfer Methods 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
206010048282 zoonosis Diseases 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
Laminated Bodies (AREA)
Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

ZA200403396A 2001-11-05 2004-05-05 High level constitutive production of anthrax protective antigen. ZA200403396B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IN1127DE2001 IN190590B (de)	2001-11-05	2001-11-05

Publications (1)

Publication Number	Publication Date
ZA200403396B true ZA200403396B (en)	2005-08-05

Family

ID=11097131

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200403396A ZA200403396B (en)	2001-11-05	2004-05-05	High level constitutive production of anthrax protective antigen.

Country Status (15)

Country	Link
US (1)	US7329513B2 (de)
EP (1)	EP1442052B1 (de)
JP (1)	JP2005510215A (de)
CN (1)	CN100347189C (de)
AT (1)	ATE484517T1 (de)
BR (1)	BRPI0117173A2 (de)
CA (1)	CA2465679A1 (de)
DE (1)	DE60143276D1 (de)
IL (1)	IL161725A0 (de)
IN (1)	IN190590B (de)
MX (1)	MXPA04004281A (de)
RU (1)	RU2288272C2 (de)
UA (1)	UA80809C2 (de)
WO (1)	WO2003040179A1 (de)
ZA (1)	ZA200403396B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA80809C2 (en) *	2001-11-05	2007-11-12		Process for preparation of protective antigen protein of anthracis with e.coli
CA2526720C (en)	2003-05-22	2013-10-22	Fraunhofer Usa, Inc.	Recombinant carrier molecule for expression, delivery and purification of target polypeptides
AU2003271835A1 (en) *	2003-06-06	2005-01-04	Avecia Limited	Process for the separation of proteins
WO2005081749A2 (en) *	2004-01-23	2005-09-09	Avanir Pharmaceuticals, Inc.	Neutralizing human antibodies to anthraxtoxin
US20060246079A1 (en) *	2003-11-14	2006-11-02	Morrow Phillip R	Neutralizing human antibodies to anthrax toxin
US7355027B2 (en)	2004-06-16	2008-04-08	Dynport Vaccine Company Llc	Bacillus anthracis protective antigen
US8101735B2 (en)	2004-06-16	2012-01-24	Health Protection Agency	Preparation of protective antigen
CN100336908C (zh) *	2004-09-10	2007-09-12	中国人民解放军军事医学科学院微生物流行病研究所	一种制备重组炭疽保护性抗原的方法及其专用表达质粒
WO2007117264A2 (en)	2005-08-03	2007-10-18	Fraunhofer Usa, Inc.	Compositions and methods for production of immunoglobulins
WO2008048344A2 (en) *	2006-02-13	2008-04-24	Fraunhofer Usa, Inc.	Bacillus anthracis antigens, vaccine compositions, and related methods
AU2007215080A1 (en)	2006-02-13	2007-08-23	Fraunhofer Usa, Inc.	Influenza antigens, vaccine compositions, and related methods
GB0607462D0 (en) *	2006-04-13	2006-05-24	Avecia Ltd	Assay
US7794732B2 (en) *	2006-05-12	2010-09-14	Oklahoma Medical Research Foundation	Anthrax compositions and methods of use and production
ATE527339T1 (de)	2006-06-30	2011-10-15	Univ Georgia	Anthrax-kohlenhydrate sowie synthese und verwendungen davon
US8420607B2 (en)	2006-06-30	2013-04-16	University Of Georgia Research Foundation, Inc.	Anthrax carbohydrates, synthesis and uses thereof
EP2178558B1 (de)	2007-07-11	2014-04-30	iBio, Inc.	Yersinia pestis-antigene, impfstoffzusammensetzungen und zugehörige verfahren
WO2009126355A2 (en) *	2008-01-28	2009-10-15	Baxter International, Inc.	Methods of increasing recombinant production of bacillus anthracis protective antigen
US8734803B2 (en)	2008-09-28	2014-05-27	Ibio Inc.	Humanized neuraminidase antibody and methods of use thereof
AU2009299615B2 (en) *	2008-10-02	2015-07-16	Pharmathene Inc.	Anthrax vaccine formulation and uses thereof
US20100183675A1 (en) *	2009-01-22	2010-07-22	Allan Watkinson	Stable vaccine compositions and methods of use
US8784819B2 (en)	2009-09-29	2014-07-22	Ibio Inc.	Influenza hemagglutinin antibodies, compositions and related methods
US20120301951A1 (en) *	2010-11-18	2012-11-29	E. I. Du Pont De Nemours And Company	Prevention of contamination of nutrient feed reservoirs & feed lines in bioreactor systems
RU2633504C1 (ru) *	2016-12-27	2017-10-12	Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН)	Штамм E.coli - продуцент полноразмерного протективного антигена Bacillus anthracis в форме вирусоподобных частиц
RU2633508C1 (ru) *	2016-12-27	2017-10-12	Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук (ФИЦ Биотехнологии РАН)	Штамм E. coli - продуцент изолированного домена 1 протективного антигена Bacillus anthracis в форме вирусоподобных частиц
CN115125224B (zh) *	2022-08-11	2023-07-18	福州大学	一种可规模化生产具有活性的dna聚合酶的方法
CN117093572A (zh) *	2023-08-24	2023-11-21	中国建设银行股份有限公司	数据补录方法、装置、设备、存储介质及产品

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5677274A (en) *	1993-02-12	1997-10-14	The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services	Anthrax toxin fusion proteins and related methods
US5591631A (en) *	1993-02-12	1997-01-07	The United States Of America As Represented By The Department Of Health And Human Services	Anthrax toxin fusion proteins, nucleic acid encoding same
US5800821A (en) *	1995-03-10	1998-09-01	New England Medical Center Hospitals, Inc.	Bacterial spores as a heat stable vaccine delivery system
GB9618107D0 (en) *	1996-08-30	1996-10-09	Secr Defence	Vaccine production
AU3550599A (en) *	1998-04-07	1999-10-25	Wisconsin Alumni Research Foundation	Enterotoxin-deficient bacillus
US20020086032A1 (en) *	1999-02-02	2002-07-04	Mahan Michael J.	Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity
WO2003055977A2 (en) *	2001-10-01	2003-07-10	Regents Of The University Of California	A method for generating overexpression of alleles in genes of unknown function
UA80809C2 (en) *	2001-11-05	2007-11-12		Process for preparation of protective antigen protein of anthracis with e.coli
US7763451B2 (en) *	2001-11-09	2010-07-27	The United States Of America As Represented By The Department Of Health And Human Services	Methods for preparing Bacillus anthracis protective antigen for use in vaccines

2001
- 2001-07-12 UA UA20040503327A patent/UA80809C2/uk unknown
- 2001-11-05 IN IN1127DE2001 patent/IN190590B/en unknown
- 2001-12-07 RU RU2004117085/13A patent/RU2288272C2/ru not_active IP Right Cessation
- 2001-12-07 WO PCT/IN2001/000215 patent/WO2003040179A1/en not_active Ceased
- 2001-12-07 CA CA002465679A patent/CA2465679A1/en not_active Abandoned
- 2001-12-07 IL IL16172501A patent/IL161725A0/xx unknown
- 2001-12-07 EP EP01274653A patent/EP1442052B1/de not_active Expired - Lifetime
- 2001-12-07 US US10/494,680 patent/US7329513B2/en not_active Expired - Fee Related
- 2001-12-07 JP JP2003542224A patent/JP2005510215A/ja active Pending
- 2001-12-07 BR BRPI0117173A patent/BRPI0117173A2/pt not_active IP Right Cessation
- 2001-12-07 AT AT01274653T patent/ATE484517T1/de not_active IP Right Cessation
- 2001-12-07 CN CNB018239226A patent/CN100347189C/zh not_active Expired - Fee Related
- 2001-12-07 MX MXPA04004281A patent/MXPA04004281A/es not_active Application Discontinuation
- 2001-12-07 DE DE60143276T patent/DE60143276D1/de not_active Expired - Lifetime
2004
- 2004-05-05 ZA ZA200403396A patent/ZA200403396B/en unknown

Also Published As

Publication number	Publication date
EP1442052B1 (de)	2010-10-13
ATE484517T1 (de)	2010-10-15
WO2003040179A1 (en)	2003-05-15
RU2288272C2 (ru)	2006-11-27
CA2465679A1 (en)	2003-05-15
RU2004117085A (ru)	2005-03-27
BRPI0117173A2 (pt)	2018-04-17
EP1442052A1 (de)	2004-08-04
JP2005510215A (ja)	2005-04-21
IN190590B (de)	2003-08-09
CN1582298A (zh)	2005-02-16
UA80809C2 (en)	2007-11-12
CN100347189C (zh)	2007-11-07
DE60143276D1 (de)	2010-11-25
US7329513B2 (en)	2008-02-12
MXPA04004281A (es)	2005-03-31
US20050054038A1 (en)	2005-03-10
IL161725A0 (en)	2005-11-20
HK1072610A1 (zh)	2005-09-02

Publication	Publication Date	Title
EP1442052B1 (de)	2010-10-13	Höhe konstitutive produktion von anthrax oberflächenschutzantigen
Hoffmann et al.	2004	Minimizing inclusion body formation during recombinant protein production in Escherichia coli at bench and pilot plant scale
İncir et al.	2024	Escherichia coli as a versatile cell factory: Advances and challenges in recombinant protein production
JP2564506B2 (ja)	1996-12-18	異種タンパク質の製造方法
Park et al.	1992	Enhanced β‐galactosidase production by high cell‐density culture of recombinant Bacillus subtilis with glucose concentration control
MX2009000813A (es)	2009-02-03	Proceso de fermentacion alimentada de alta densidad celular para producir proteinas recombinantes.
RU2003122076A (ru)	2005-02-27	Способ ферментативного получения аминокислот и производных аминокислот из семейства фосфоглицератов
CA2896157A1 (en)	2014-07-03	Methods and compositions relating to crm197
EP1527188B1 (de)	2010-01-27	Verfahren zur herstellung erhöhter mengen an richtig gefalteten heterologen proteinen in einschlussteilchen
CN112831488A (zh)	2021-05-25	一种谷氨酸脱羧酶及γ-氨基丁酸高产菌株
Kumar et al.	2022	Slow post-induction specific growth rate enhances recombinant protein expression in Escherichia coli: Pramlintide multimer and ranibizumab production as case studies
Tripathi et al.	2009	METHODS: Optimization of culture medium for production of recombinant dengue protein in Escherichia coli
Weng et al.	2006	Optimization of the overexpression of glutamate mutase S component under the control of T7 system by using lactose and IPTG as the inducers
EP1453981A1 (de)	2004-09-08	Methylotrophes bakterium zur produktion rekombinanter proteine und anderer produkte
US5856142A (en)	1999-01-05	Method for the extraction of periplasmic proteins from prokaryotic microorganisms in the presence of arginine
CN107760642A (zh)	2018-03-06	一种能高效分解甲酰胺和氧化亚磷酸盐的重组大肠杆菌及其构建方法与应用
RU2242516C1 (ru)	2004-12-20	Способ получения рекомбинантного человеческого интерферона альфа-2b, рекомбинантная плазмида и штамм продуцент для его осуществления
HK1072610B (en)	2008-05-02	High level constitutive production of anthrax protective antigen
Panda et al.	1995	High cell density fermentation of recombinant Vibrio cholerae for the production of B subunit of Escherichia coli enterotoxin
Shiloach et al.	2010	Bacterial cultivation for production of proteins and other biological products
US20250011382A1 (en)	2025-01-09	Method for the manufacture of biopharmaceuticals
US20030157636A1 (en)	2003-08-21	Methylotrophic bacterium for the production of recombinant proteins and other products
RU2451750C2 (ru)	2012-05-27	Способ получения рекомбинантного с-пептида проинсулина человека
Ding et al.	2021	ITH PERMISSION O
EP2370590B1 (de)	2014-03-12	Verfahren zur herstellung des actinobacillus pleuropneumoniae toxins apxi unter verwendung eines calcium-borogluconat enthaltenden kulturmediums